Citations

Clear

7732 citation(s) found for "Ma, Daniel".

GLUT9b- and ABCG2-mediated collecting duct urate transport uncovers a vasopressin-independent mechanism of renal water reabsorption
Hadla, Mohamad , Mardirossian, Jean Marc , Bichet, Daniel, Borghol, Abdul Hamid , Abboud, Georges, Ghanem, Ahmad , Chini, Eduardo N., Harris, Peter, Alper, Seth L., Vallon, Volker , Chini, Eduardo, Hadla, Mohamad , Vallon, Volker , Bichet, Daniel Georges , Abboud, Georges , Chini, Eduardo N. , Harris, Peter C. , Torres, Vicente E. , Alper, Seth L. , Chebib, Fouad T.

Mayo Clinic

Journal of Clinical Investigation | June 16, 2026 | Volume: 136 | Issue: 14 | Pages: No page available

10.1172/jci197021 | PMID 42298327 Get It

Renal water reabsorption is classically regulated by vasopressin V2 receptor (V2R) signaling through cyclic AMP and protein kinase A, driving apical accumulation of aquaporin-2 (AQP2). However, collecting duct water handling is also modulated by vasopressin-independent mechanisms. Here, we examined intracellular soluble urate as a vasopressin-independent regulator of AQP2 trafficking. Intracellular urate accumulation in collecting duct cells was mediated by enhanced apical urate uptake via GLUT9b and reduced apical urate efflux through ABCG2, triggering phosphodiesterase-4 activation, reduced cAMP, and downstream AMP-activated protein kinase (AMPK) activation. The resulting AQP2 accumulation at the apical membrane was independent of V2R signaling, required ongoing endocytosis, and was associated with features of postendocytic apical trafficking of internalized AQP2. In vivo ABCG2 inhibition with probenecid increased apical AQP2 abundance and markedly attenuated tolvaptan-induced polyuria in both wild-type and Pkd1 RC/RC autosomal dominant polycystic kidney disease (ADPKD) mice in a uricase-independent manner while preserving tolvaptan’s ADPKD-modifying efficacy. In a phase II trial with tolvaptan-treated patients with ADPKD, probenecid reduced urine volume and nocturia frequency. Together, these findings support a vasopressin-independent urate/AMPK/AQP2 pathway that regulates renal water handling and, in a preclinical ADPKD model, can uncouple cyst growth attenuation from the dose-limiting aquaretic effects of V2R antagonism.
Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma
Garcia, David M., Lin, Wan‐Hsin , Wickland, Daniel P. , Jessen, Erik , Middlebrooks, Erik H. , Haydu, Lauren E. , Brooks, Mieu , Feathers, Ryan W. , Kinsella, Lindsey , Sereduk, Chris , Rosenfeld, Steven S. , Chaichana, Kaisorn L. , Anastasiadis, Panos Z. , Quiñones‐Hinojosa, Alfredo , Jessen, Erik , Tran, Nhan L , Chaichana, Kaisorn L , Anastasiadis, P Z , Quinones-Hinojosa, Alfredo , Middlebrooks, Erik H , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noag139 | PMID 42296327 Get It

Abstract Background Glioblastoma (GBM) remains a devastating cancer with limited treatment options, largely due to its heterogeneity. While supramaximal resection has recently provided survival benefits, therapeutic profiling of different tumor compartments, particularly its infiltrative edge remains largely unexplored. Methods Here, we leveraged magnetic resonance imaging (MRI)-guided multi-sampling, collecting 2 cores and 2 margins per case, to query GBM heterogeneity. Whole-exome and RNA-seq with drug testing in two patient-derived 3D models were used to reveal similarities and differences in genomic and transcriptomic makeups, cellular compositions, and drug responses across cores and margins. Bioinformatics interrogations further identified response biomarkers. Results Mutation analysis showed that oncogenes exhibited a higher degree of spatial heterogeneity than tumor suppressor genes, regardless of MRI status. While the mesenchymal transcriptional subtype with extracellular matrix remodeling, stress response, and immune programs were preferentially enriched in enhancing cores, proneural tumors with neurological processes favored non-enhancing margins. Using a 15-drug GBM-targeted panel, ERK (ulixertinib) and PI3K pathway (paxalisib, CC-115) inhibitors showed preferential efficacy in enhancing cores and non-enhancing margins, respectively. The anti-apoptosis, pan-Bcl2 agent navitoclax and the epigenetic drug trotabresib represented the most effective, tumor-wide monotherapies. Importantly, drug combinations generally outperformed single agents across all regions. Conclusions This work demonstrates the regional heterogeneity of therapeutic vulnerabilities in GBM ex vivo, showing various drugs with tumor-wide or MRI-enhancement informed activity. These findings offer preclinical bases of numerous monotherapies and drug combinations for future clinical trial design.
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Johnson, Douglas, Albertini, Mark R. , Barker, C. A., Bateni, Sarah, Baumgartner, Joel, Bichakjian, Christopher, Boland, Genevieve , Chandra, Sunandana , Chen, David, Choi, Jacob, DiMaio, Dominick, Dronca, Roxana, Fleming, Martin D. , Galan, Anjela , Guild, Samantha, Hu-Lieskovan, Siwen, Karakousis, Giorgos, Kendra, Kari, Kiuru, Maija, Lange, Julie R., Lanning, Ryan, Logan, Theodore, Materin, Miguel, Nelson, Kelly, Olson, Daniel, Pa, Ott, Puzanov, Igor, Rothermel, Luke, Salama, April K., Shannon, Adrienne, Singh, Arun, Stacey, Andrew, Tsai, Katy, Wuthrick, Evan, Xing, Yan, McMillian, Nicole, Espinosa, Sara, Swetter, Susan M. , Johnson, Douglas B., Barker, Christopher A. , Baumgartner, Joel , Bhatia, Shailender , Bichakjian, Christopher K. , Chmielowski, Bartosz , DiMaio, Dominick J. , Guild, Samantha, Hu‐Lieskovan, Siwen , Karakousis, Giorgos C. , Kiuru, Maija H. , Lanning, Ryan M. , Logan, Theodore F. , Materin, Miguel Angel , Nelson, Kelly C., Olson, Daniel , Olszanski, Anthony J. , Puzanov, Igor , Rothermel, Luke D. , Salama, April K.S. , Sharma, Rohit , Wuthrick, Evan , McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 15, 2026 | Volume: 24 | Issue: 6 | Pages: 272-277

10.6004/jnccn.2026.0027 | PMID 42297031 Get It

The NCCN Guidelines for Melanoma: Cutaneous provide strategies for the diagnosis, treatment, and follow-up of patients with cutaneous melanoma, which is among the most common cancers in the United States. The outcome of cutaneous melanoma is significantly influenced by stage at initial presentation. Generally, localized disease and smaller primary tumors have been associated with more favorable prognosis. Thus, the select content featured in this issue focuses on risk factors associated with cutaneous melanoma development and which should be considered during an initial assessment. These include (1) phenotypic predispositions, (2) personal medical history or comorbidities, (3) genetic predispositions, and (4) environmental factors.
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026
Patel, Anand , Patel, Anand , Pollyea, Daniel Aaron , Altman, Jessica K. , Assi, Rita, Bachiashvili, Kimo, Bhatt, Vijaya Raj , Fathi, Amir T. , Fedorov, Kateryna, Foran, James M. , Gojo, Ivana , Goldberg, Aaron, Hall, Aric C. , Jonas, Brian A., Levine, Matthew R., Mangan, James, Mannis, Gabriel N. , Marcucci, Guido , Mims, Alice S , Moriarty, Kelsey, Ali, Moaath Mustafa, Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Patel, Anand, Percival, Mary‐Elizabeth M. , Perl, Alexander E. , Pettit, Kristen, Rao, Dinesh S. , Ravandi‐Kashani, Farhad, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Stone, Richard M. , Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 15, 2026 | Volume: 24 | Issue: 6 | Pages: 222-229

10.6004/jnccn.2026.0028 | PMID 42297017 Get It

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. 1 The NCCN Guidelines Panel for AML convenes annually to update recommendations for the diagnosis and treatment of AML in adults. These recommendations are based on a review of recently published clinical trials that have led to significant improvements in treatment or have yielded new information regarding biologic factors that may have prognostic importance. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding the monitoring and management of measurable (minimal) residual disease.
An Annual Review of Important Apheresis Articles in 2025 From the American Society for Apheresis Attending Physician Subcommittee
Zantek, Nicole D. , Lu, Wen , AlMozain, Nour , Lu, Wen , Almozain, Nour , Alsammak, Mohamed , Gupta, Gaurav K , Levenbrown, Yosef , Li, Yanhua , Tripathi, Parmatma Prasad , Tanhehco, Yvette C , Zantek, Nicole D , Dilly, Laura, Martin, Marisa C. Saint, Alsammak, Mohamed , Banez‐Sese, Grace, Chhibber, Vishesh, Costa, Victoria, DeChristopher, Phillip J., Durlen, Ivan , Gupta, Gaurav K. , Li, Yanhua , Mattiazzi, Adela D. , Noland, Daniel K., Prajapati, Vipulkumar, Singh, Nirupama, Siwach, Garima, Wu, Ding Wen , Wehrli, Gay , Tanhehco, Yvette C.

Mayo Clinic

Journal of Clinical Apheresis | June 13, 2026 | Volume: 41 | Issue: 3 | Pages: No page available

10.1002/jca.70142 | PMID 42287024 Get It

ABSTRACT Apheresis medicine is a continually evolving field with numerous studies published each year. To help apheresis practitioners stay up to date with the current literature, members of the American Society for Apheresis (ASFA) Attending Physician Subcommittee identified and summarized 10 seminal articles published in 2025, from the field of apheresis medicine. PubMed was used to identify articles published in four topics including donor apheresis, therapeutic apheresis, apheresis education, and apheresis collection for cellular therapy. These articles met at least one of the following criteria: novel findings, practice‐altering outcomes, international in scope, randomized‐controlled trial, relevant to current clinical practice, and/or provide evidence for category III or IV indications based on the ASFA 9th Special Issue of the Guidelines on the Use of Therapeutic Apheresis in Clinical Practice‐Evidence‐Based Approach. Full length, peer‐reviewed manuscripts in English with data from human subjects were included while case reports, review articles, and meta‐analyses were excluded.
Circadian control of innate immunity: molecular mechanisms and implications for allergic disorders
Nahas, Ammar, Lupi, D, Colao, Beatriz Nuñez, SACCO, KEITH, Lupi, Daniel Zammit

Mayo Clinic

Current Opinion in Allergy & Clinical Immunology | June 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/aci.0000000000001176 | PMID 42286958 Get It

Purpose of review Circadian clocks are increasingly recognized as fundamental regulators of innate immune function, yet their relevance to allergy and clinical immunology has only recently been clarified. This review summarizes emerging evidence linking circadian regulation of innate immune cells to allergic inflammation and highlights the translational potential of circadian-informed therapeutic strategies. Recent findings Core clock components are rhythmically expressed in macrophages, mast cells, neutrophils and innate lymphoid cells, where they regulate inflammatory signalling, immunometabolism and activation thresholds. Disruption of these rhythms exaggerates cytokine production, inflammasome activation and mast cell mediator release, contributing to diurnal patterns of allergic disease such as nocturnal asthma. Human and experimental studies demonstrate that circadian misalignment driven by shift work, irregular sleep and mistimed feeding amplifies innate inflammation and worsens allergic outcomes. Summary Circadian regulation represents an underappreciated dimension of innate immunity in allergic disease. Aligning immunomodulatory therapies, vaccination, and lifestyle interventions with endogenous immune rhythms offers a rational approach to improving efficacy and reducing inflammatory burden. Future studies should prioritize time-stratified clinical trials and direct circadian phenotyping in allergic populations.
Prior Calf Strain as a Risk Factor for Achilles Tendon Rupture in National Basketball Association Players: A Retrospective Analysis
Elsabbagh, Zaid , Le, Ysa, Bcharah, George , Ryu, David , Hsu, Nigel , Thompson, John Michael, Aiyer, Amiethab, Le, Ysa , Ryu, David , Badin, Daniel , Thompson, John Michael, Aiyer, Amiethab A.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | June 12, 2026 | Volume: 14 | Issue: 6 | Pages: No page available

10.1177/23259671261449170 | PMID 42293040 Get It

Background: Achilles tendon ruptures are among the most debilitating injuries in professional basketball, often leading to prolonged absence and long-term performance decline. While calf strains are common among National Basketball Association (NBA) athletes, their role as a precursor to Achilles rupture remains poorly understood. Hypothesis: A previous calf strain would be associated with increased odds of Achilles tendon rupture in NBA players and that affected players would experience significant post-injury performance declines. Study Design: Case-cohort study; Level of evidence, 3. Methods: Publicly available data on NBA players from 1958 to 2024 were analyzed, with the data search conducted in June 2025. Players with Achilles ruptures (n = 60) were compared with players with calf strains who did not sustain a rupture (n = 258). Logistic regression adjusted for age, body mass index, position, starter status, and workload. Pre- and postinjury performance was evaluated over 2 seasons using paired t tests. Descriptive analyses characterized injury laterality, game context, quarter, shoe type, and draft position. Video review assessed injury mechanisms. Results: Previous calf strain was associated with increased odds of Achilles rupture (odds ratio, 2.49; 95% CI, 1.16-5.22; P = .02). Among those with both injuries, 85.7% occurred on the same side, with a mean interval of 1.9 years. Of all players, a total of 75% returned to play. Postinjury declines were observed in player efficiency rating (−2.46), win shares (−3.23), games played (−260.3), and minutes per game (−5.19) (all P < .001). Return was more likely in younger players and those on multiyear contracts. Video analysis revealed a consistent “false step” mechanism in 95% of cases with footage. Most Achilles tendon ruptures occurred during in-game activity, while shoe type was evaluated descriptively and was not associated with player position or preinjury workload. Conclusion: Our study showed that previous calf strain is associated with an increased risk of Achilles tendon rupture in NBA players and may serve as a clinically identifiable risk marker. Rupture leads to substantial and sustained performance decline, even among those who return. Targeted rehabilitation and movement retraining may help mitigate progression to rupture in high-risk athletes.
Anatomic Basis for Imaging Assessment of the Postsurgical Anterolateral Abdominal Wall
Montel, Daniel B. , Oliveira, I. , Salazar, Max Orsi , FIOROT, VINICIUS CASTRO DE REZENDE , Gontijo, Cássio Eduardo da Silva , Horvat, Natally , Venâncio, Priscilla Cláudia Raddo , Barbosa, Manoel Henrique Fonseca , Chaves, Filipe Tomishige , Pozzer, Gabriel Guilherme Nunes , Lewin, Fábio , Montel, Daniel Borges , de Oliveira, Igor Rother César , Orsi Salazar, Max , Horvat, Natally

Mayo Clinic

RadioGraphics | June 11, 2026 | Volume: 46 | Issue: 7 | Pages: No page available

10.1148/rg.250061 | PMID 42275240 Get It

A structured approach for interpreting postoperative imaging of the anterolateral abdominal wall integrates anatomic knowledge with surgical techniques and their associated complication patterns.
Radiology: Cardiothoracic Imaging Highlights 2025
Sanchez, Daniel Alfonso Pinos , Farias, Lucas de Pádua Gomes de , Onnis, Carlotta , Escalon, Joanna G. , Hanneman, Kate , Litt, Harold , Gulsin, Gaurav S. , Pinos, Daniel , Gomes de Farias, Lucas de Pádua , Suchá, Dominika , Escalon, Joanna G , Hanneman, Kate , Abbara, Suhny , Litt, Harold I , Gulsin, Gaurav S , Suchá, Dominika , Mastrodicasa, Domenico

Mayo Clinic

Radiology: Cardiothoracic Imaging | June 11, 2026 | Volume: 8 | Issue: 3 | Pages: No page available

10.1148/ryct.260065 | PMID 42274320 Get It

Articles published in Radiology: Cardiothoracic Imaging in 2025 highlight advances in cardiothoracic imaging through technical innovation, quantitative biomarkers, and artificial intelligence applications that support improved diagnosis, risk stratification, and patient-centered management across cardiac, vascular, and thoracic disease.